A window-of-opportunity study on breast cancer also showed that Reparixin, an oral tablet of CXCR1/2 inhibitor, reduced the cancer stem cells (CSCs) content and appeared safe and well-tolerated among the treated patients [84]. The gene discussed is CXCR1; the disease is cancer.